Internalization and Endosomal Degradation of Receptor-bound Antigens Regulate the Efficiency of Cross Presentation by Human Dendritic Cells
Overview
Authors
Affiliations
Dendritic cells (DCs) can capture extracellular antigens and load resultant peptides on to MHC class I molecules, a process termed cross presentation. The mechanisms of cross presentation remain incompletely understood, particularly in primary human DCs. One unknown is the extent to which antigen delivery to distinct endocytic compartments determines cross presentation efficiency, possibly by influencing antigen egress to the cytosol. We addressed the problem directly and quantitatively by comparing the cross presentation of identical antigens conjugated with antibodies against different DC receptors that are targeted to early or late endosomes at distinct efficiencies. In human BDCA1+ and monocyte-derived DCs, CD40 and mannose receptor targeted antibody conjugates to early endosomes, whereas DEC205 targeted antigen primarily to late compartments. Surprisingly, the receptor least efficient at internalization, CD40, was the most efficient at cross presentation. This did not reflect DC activation by CD40, but rather its relatively poor uptake or intra-endosomal degradation compared with mannose receptor or DEC205. Thus, although both early and late endosomes appear to support cross presentation in human DCs, internalization efficiency, especially to late compartments, may be a negative predictor of activity when selecting receptors for vaccine development.
Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.
Huang L, Huang Z, Zhang Y, Lin C, Zhao Z, Li R Theranostics. 2024; 14(14):5528-5550.
PMID: 39310113 PMC: 11413781. DOI: 10.7150/thno.93745.
Wu Z, Huang C Int J Gen Med. 2024; 17:2575-2592.
PMID: 38855425 PMC: 11162242. DOI: 10.2147/IJGM.S461144.
Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease.
Obare L, Temu T, Mallal S, Wanjalla C Circ Res. 2024; 134(11):1515-1545.
PMID: 38781301 PMC: 11122788. DOI: 10.1161/CIRCRESAHA.124.323891.
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q Mol Cancer. 2023; 22(1):187.
PMID: 38008741 PMC: 10680233. DOI: 10.1186/s12943-023-01885-w.
Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors.
Wijfjes Z, van Dalen F, Le Gall C, Verdoes M Mol Pharm. 2023; 20(10):4826-4847.
PMID: 37721387 PMC: 10548474. DOI: 10.1021/acs.molpharmaceut.3c00330.